Professors David Beratan and Peng Zhang, with collaborators at NYU and ASU, have designed, built, and demonstrated current splitters and charge-transport junctions based on self-assembling nucleic acids. These constructs promise to expand the functionality of self-assembling bio-inspired electron
The Malcolmson lab has demonstrated that olefins may act as alkylating agents for the enantioselective intermolecular addition of enol-type nucleophiles under Pd catalysis.
The high temperatures and intense UV irradiation of the early earth made DNA particularly susceptible to damage. Beratan’s group used theory, modeling, and simulation to explore the mechanism of photochemical repair of damaged DNA by the enzyme photolyases.
The de novo design of a protein capable of binding a cofactor in a unique orientation is a challenging problem because a range of structurally similar, yet different, complexes are often formed. Now, a team led by former graduate student Nick Polizzi and by Professors David N.
The Malcolmson lab has reported a new class of reagents, 2-azadienes, for the catalytic enantioselective construction of chiral amines. The 2-azadienes demonstrate reverse polarity (umpolung) of an enamine, facilitating catalytic addition of a nucleophile to its N-b-carbon and subsequent stereos
Biology is well known to manipulate energy using proton-coupled electron transfer and phosphorylation reactions. It was found recently that energy conversion can also occur via a new class of reactions, known as electron bifurcation reactions.
The Wang, Malcolmson and Warren labs have teamed up to use diazirines as molecular imaging tags for biomedical applications.
Equilibrating glass-forming liquids is notoriously hard; Duke chemists and their collaborators in France have developed a way to circumvent this obstacle, enabling studies of extremely sluggish liquids.
A recent publication in Nature Communications on selective carbon dioxide hydrogenation using plasmonic rhodium catalysts by the Liu lab and collaborators has been selected as one of eight featured articles in the
The Hargrove Lab compared bioactive ligands that target RNA to current FDA-approved drugs, nearly all of which target proteins. With the help of the Beratan Lab, they identified key differences in physical, structural, and spatial properties that distinguish RNA-targeted bioactive ligands.
